Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Unum Therapeutics Inc (UMRX) USD0.001

Sell:$0.52 Buy:$0.52 Change: $0.0108 (2.10%)
NASDAQ:0.43%
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
Sell:$0.52
Buy:$0.52
Change: $0.0108 (2.10%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
Sell:$0.52
Buy:$0.52
Change: $0.0108 (2.10%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.

Contact details

Address:
200 Cambridgepark Dr Ste 3100
CAMBRIDGE
02140-2307
United States
Telephone:
+1 (617) 9455576
Website:
https://www.unumrx.com/

Important dates